Proof of concept of triple COMBI therapy to prohibit MPN progression to AML

Hans Carl Hasselbalch; Vibe Skov; Lasse Kjaer; Morten Kranker Larsen

doi:10.1111/bjh.19173

Proof of concept of triple COMBI therapy to prohibit MPN progression to AML

Hans Carl Hasselbalch^*
, Vibe Skov
, Lasse Kjaer
, Morten Kranker Larsen

^*Corresponding author for this work

Haematology

Research output: Contribution to journal › Comment/debate › Research

Abstract

Patients with accelerated or blast phase myeloproliferative neoplasms have a dismal prognosis. The report by de Castro et al. provides important information on the rationale and prospect for a novel therapeutic approach combining interferon-alpha2 with 5-azacytidine and a JAK1-2 inhibitor (ruxolitinib) to be explored in well-designed clinical trials. Commentary on: Castro et al. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia. Br J Haematol 2024;204:206-220.

Original language	English
Pages (from-to)	16-18
Number of pages	3
Journal	British Journal of Haematology
Volume	204
Issue number	1
Early online date	13 Nov 2023
DOIs	https://doi.org/10.1111/bjh.19173
Publication status	Published - Jan 2024

Keywords

Azacitidine/therapeutic use
Humans
Interferons/therapeutic use
Leukemia, Myeloid, Acute/drug therapy
Myeloproliferative Disorders/drug therapy
Prognosis

Access to Document

10.1111/bjh.19173Licence: CC BY-NC

Cite this

@article{971d1f31828e45eea1666b519bebb278,

title = "Proof of concept of triple COMBI therapy to prohibit MPN progression to AML",

abstract = "Patients with accelerated or blast phase myeloproliferative neoplasms have a dismal prognosis. The report by de Castro et al. provides important information on the rationale and prospect for a novel therapeutic approach combining interferon-alpha2 with 5-azacytidine and a JAK1-2 inhibitor (ruxolitinib) to be explored in well-designed clinical trials. Commentary on: Castro et al. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia. Br J Haematol 2024;204:206-220.",

keywords = "Azacitidine/therapeutic use, Humans, Interferons/therapeutic use, Leukemia, Myeloid, Acute/drug therapy, Myeloproliferative Disorders/drug therapy, Prognosis",

author = "Hasselbalch, \{Hans Carl\} and Vibe Skov and Lasse Kjaer and Larsen, \{Morten Kranker\}",

note = "{\textcopyright} 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley \& Sons Ltd.",

year = "2024",

month = jan,

doi = "10.1111/bjh.19173",

language = "English",

volume = "204",

pages = "16--18",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons Inc.",

number = "1",

}

TY - JOUR

T1 - Proof of concept of triple COMBI therapy to prohibit MPN progression to AML

AU - Hasselbalch, Hans Carl

AU - Skov, Vibe

AU - Kjaer, Lasse

AU - Larsen, Morten Kranker

PY - 2024/1

Y1 - 2024/1

N2 - Patients with accelerated or blast phase myeloproliferative neoplasms have a dismal prognosis. The report by de Castro et al. provides important information on the rationale and prospect for a novel therapeutic approach combining interferon-alpha2 with 5-azacytidine and a JAK1-2 inhibitor (ruxolitinib) to be explored in well-designed clinical trials. Commentary on: Castro et al. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia. Br J Haematol 2024;204:206-220.

AB - Patients with accelerated or blast phase myeloproliferative neoplasms have a dismal prognosis. The report by de Castro et al. provides important information on the rationale and prospect for a novel therapeutic approach combining interferon-alpha2 with 5-azacytidine and a JAK1-2 inhibitor (ruxolitinib) to be explored in well-designed clinical trials. Commentary on: Castro et al. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia. Br J Haematol 2024;204:206-220.

KW - Azacitidine/therapeutic use

KW - Humans

KW - Interferons/therapeutic use

KW - Leukemia, Myeloid, Acute/drug therapy

KW - Myeloproliferative Disorders/drug therapy

KW - Prognosis

U2 - 10.1111/bjh.19173

DO - 10.1111/bjh.19173

M3 - Comment/debate

C2 - 37957927

SN - 0007-1048

VL - 204

SP - 16

EP - 18

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Proof of concept of triple COMBI therapy to prohibit MPN progression to AML

Abstract

Keywords

Access to Document

Fingerprint

Cite this